1991
Cyclosporin A renders target cells resistant to immune cytolysis
Hudnall S. Cyclosporin A renders target cells resistant to immune cytolysis. European Journal Of Immunology 1991, 21: 221-226. PMID: 1846819, DOI: 10.1002/eji.1830210133.Peer-Reviewed Original ResearchConceptsCsA dose reductionB-cell hyperplasiaB lymphocytesDose reductionCell growth inhibitionNatural killerCell hyperplasiaEarly post-transplant lymphoproliferative disordersHuman organ transplant recipientsPost-transplant lymphoproliferative disorderT cell-dependent responsesAntibody-dependent responsesPost-transplant settingOrgan transplant recipientsTarget cellsEpstein-Barr virusCell-dependent responsesHuman target cellsComplement-mediated cytolysisGrowth inhibitionTransplant recipientsDisease regressionImmune controlNK cellsLymphoproliferative disorders
1987
Role of CD8+ and CD8- Cytolytic Effectors in IL2 Reversal of Cyclosporin-Inhibited EBV-B-Cell Cytotoxicity
Hudnall S, Kurbe M. Role of CD8+ and CD8- Cytolytic Effectors in IL2 Reversal of Cyclosporin-Inhibited EBV-B-Cell Cytotoxicity. Experimental Biology And Medicine 1987, 513-515. DOI: 10.1007/978-1-4612-4590-2_110.Peer-Reviewed Original ResearchEpstein-Barr virusPeripheral blood mononuclear cellsRecombinant interleukin-2Interleukin-2B cellsAutologous Epstein-Barr virusB95-8 Epstein-Barr virusRole of CD8NK cell cytotoxicityOrgan transplant recipientsBlood mononuclear cellsForm of cytotoxicityReactivation infectionTransplant recipientsSuppressor/Effector phenotypeMalignant lymphomaCytolytic effectorsMononuclear cellsT cellsCell cytotoxicityCyclosporin ADrug cyclosporin ACsACytotoxicity